How many modules are there in GVP?
How many modules are there in GVP?
Background to public consultation on GVP This new guidance on good pharmacovigilance practices (GVP) is organised into Modules, and the first seven Modules on prioritised topics are now available for public consultation.
What is GVP Module VI?
GVP Module VI: Management and Reporting of Adverse Reactions to Medicinal Products. This course is primarily aimed at individuals who are either new to Pharmacovigilance or who work in departments within the pharmaceutical industry that work closely with drug safety e.g. all Medical Information professionals.
What is a controlled distribution system?
A controlled distribution system refers to the set of measures implemented to ensure that the stages of the distribution chain of a medicinal product are tracked up to the prescription and/or pharmacy dispensing the product.
What is pharmacovigilance practice?
A set of measures drawn up to facilitate the performance of the safety monitoring of medicines in the European Union. Abbreviated as GVP. More information can be found under Good pharmacovigilance practices.
Who must ensure that they have appropriate measures in place to collate all the reports of suspected adverse reactions?
states: “Competent authorities and marketing authorisation holders should take appropriate measures to collect and collate all reports of suspected adverse reactions associated with medicinal products for human use originating from unsolicited or solicited sources.”
What are the GVP guidelines?
Good pharmacovigilance practices (GVP) are a set of measures drawn up to facilitate the performance of pharmacovigilance in the European Union (EU). GVP apply to marketing-authorisation holders, the European Medicines Agency (EMA) and medicines regulatory authorities in EU Member States.
What is a valid Icsr?
A valid ICSR should include at least one identifiable reporter, one single identifiable patient, at least one suspect adverse reaction and at least one suspect medicinal product.”
What are additional risk minimization measures?
Risk minimisation measures are interventions intended to prevent or reduce the occurrence of adverse reactions. Risk minimisation measures can either be routine measures (e.g. SmPC, PIL, prescription status of product) or additional measures. Additional measures are used to improve benefit-risk profile of medicines.
What is rechallenge and Dechallenge in pharmacovigilance?
not conclusive indication of drug-induced disease. • In cases where a withdrawal reaction is experienced, a dechallenge is when. the drug is again given to the patient. • “Positive” dechallenge = improvement of reaction when dechallenge occurs. Rechallenge = reintroducing the drug after a dechallenge.
When is GVP module VI guideline effective date?
GVP module VI Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products (Rev 1) Effective date: 16-09-2014 By: Dr. Bipin Chandra Bhagath.
Who is the author of GVP module VI?
Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products (Rev 1) Effective date: 16-09-2014 By: Dr. Bipin Chandra Bhagath. Unspecified & Type of ADR 2. Only outcome/Consequence 3. No clinical circumstances 4.
What are the GVP modules for pharmacovigilance?
GVP modules I to XVI cover major pharmacovigilance processes and the development of this set of guidance is concluded. The module numbers XI, XII, XIII and XIV stay void, as their planned topics have been addressed by other guidance documents on the Agency’s website (see bullet points below Final GVP modules table).
What are the chapters of the GVP guideline?
The guideline on GVP is divided into chapters that fall into two categories: modules covering major pharmacovigilance processes; product- or population-specific considerations.
